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1. Introduction 
The generation of human induced pluripotent stem human (iPS) cells from human cells by 
only chemicals is not reported. On the other hand, loss of microRNA-145 elevates Oct3/4, 
Sox2 and Klf4 (1). Furthermore, TGF beta ligand elevates Sox2 (2). Therefore, when we can 
find human cells with endogenous expressions of Oct 3/4 and Sox2, even if their 
expressions were slight, it would be possible for us to generate the human iPS cells from the 
cells by using micro RNA-145 inhibitor and/or TGF beta ligand as chemicals appropriately. 
2. Materials and methods 
2.1 Cell culture 
2.1.1 Human liver biopsy specimens 
Formalin-fixed and paraffin-embedded human postliving donor transplant liver biopsy 
specimens were obtained in our institutes. Liver biopsies from 10 living donor transplant 
recipients were collected at 1 week (two specimens), 6 weeks (five specimens), and 12 weeks 
(three specimens) posttransplant as part of a standardized protocol to rule out liver 
pathology following living donor transplantation. Zero specimens were collected to 
evaluate for suspected rejection. All human tissue procedures were approved by the 
Institutional Review Board. Oct3/4 positive cells were observed in specimens from all 
timepoints posttransplantation. In specimens from 1 week, Oct3/4 positive cells were 
present in a contiguous streaking manner from the central vein. 
2.2 Induction of human iPS cells 
For generation of human iPS cells, human liver progenitor cells with Oct 3/4 positive were 
derived from human liver biopsy specimens at first. Next, the cells were seeded at a density 
of 53104 cells per 6-well plate in human embryonic stem (hES) cells medium. The human 
liver progenitor cells with Oct3/4 positive were treated with 2'OMe-miR-145 as micro RNA-
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145 inhibitor (100 nmol/L; 168 hours, after that, 50 nmol/L;72 hours) and TGF-beta ligand 
(100 pM; 48 hours) in the hES cells medium.  
Furthermore, the human iPS cell (hES cells-like) colonies were mechanically isolated and 
were subsequently re-plated and maintained on CF1 mouse feederlayers (Millipore) in hES 
cell medium. 
2.3 Western blotting 
The cells at semiconfluent state were lysed with RIPA buffer (50 mM Tris-HCl, pH 8.0, 
150mMNaCl, 1% Nonidet P-40 (NP-40), 1% sodium deoxycholate, and 0.1% SDS), 
supplemented with protease inhibitor cocktail (Roche). The cell lysate of MEL-1 hES cell line 
was purchased from Abcam. Cell lysates (20 mg) were separated by electrophoresis on 8% 
or 12% SDS-polyacrylamide gel and transferred to a polyvinylidine difluoride membrane 
(Millipore). The blot was blocked with TBST (20 mM Tris-HCl, pH 7.6, 136 mM NaCl, and 
0.1% Tween-20) containing 1% skim milk and then incubated with primary antibody 
solution at 4 °C overnight. After washing with TBST, the membrane was incubated with a 
horseradish peroxidase (HRP)-conjugated secondary antibody for 1 hr at room temperature. 
Signals were detected with Immobilon Western chemiluminescent HRP substrate 
(Millipore) and LAS3000 imaging system (FUJIFILM, Japan). Antibodies used for western 
blotting were anti-Oct3/4 (1:600, Santa Cruz), anti-Sox2 (1:2000, Chemicon), anti-Nanog 
(1:200, R&D Systems), anti-Klf4 (1:200, Santa Cruz), anti-c-Myc (1:200, Santa Cruz), anti-E-
cadherin (1:1000, BD Biosciences), anti-β-catenin (1:200, BD Biosciences), anti-β-actin (1:5000, 
Sigma), anti-mouse IgG-HRP (1:3000, Cell Signaling), anti-rabbit IgG-HRP (1:2000, Cell 
Signaling), and antigoat IgG-HRP (1:3000, Santa Cruz). 
2.4 Immunocytochemistry  
Cultured cells were fixed with 10% formaldehyde for 10 min and blocked with 0.1% 
gelatin/PBS at room temperature for 1 hr. The cells were incubated overnight at 4°C with 
primary antibodies against SSEA-4 (MC813-70; Chemicon), TRA-1-60 (ab16288; abcam), 
TRA-1-81 (ab16289; abcam), or Nanog (MAB1997; R&D Systems), AFP (Sigma), cTNT 
(NeoMarkers), DESMIN (Lab Vision), GFAP (DAKO), NKX2.5 (Santa Cruz Biotechnology), 
PDX1 (R&D systems), SMA (Sigma), SOX17 (R&D systems), TH (Chemicon), bIII-
tubulin(Covance Research Products). 
For Nanog staining, cells were permeabilized with 0.1 % Triton X-100/PBS before blocking. 
The cells were washed with PBS three times, then incubated with Alexa Fluor 488-
conjugated secondary antibodies (Molecular Probes) and Hoechst 33258 (Nacalai) at room 
temperature for 1 hr. After further washing, fluorescence was detected with an Axiovert 
200M microscope (Carl Zeiss). 
2.4.1 qRT–PCR  
Total RNA was isolated from bulk cell culture samples or handpicked undifferentiated 
colonies using RNeasy columns (Qiagen) with oncolumn DNA digestion. cDNA was 
produced using oligo-dT15 priming and M-MLV reverse transcriptase (USB) according to 
the manufacturer’s instructions at 42 uC for 1 h. About 50 ng of total RNA equivalent was 
typically used as template in 20 ml SYBR green PCR reactions (40 cycles of 15 s, 95 uC/60 s, 
60 uC on Applied Biosystems 7300 instrumentation) that additionally contained 0.375 mM 
of each primer and 10 ml of SYBR green PCR mix (ABI). All primers used were confirmed to 
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amplify the predicted product at close-to-optimal efficiency without side products. Relative 
expression levels were calculated using the comparative Ct method, based on biological 
control samples and two housekeeping genes for normalization.  
2.5 In vitro differentiation of human iPS cells 
For immunocytochemistry, embryoid bodies (EBs) were generated from iPS cells with the 
hanging-drop method in MEF-conditioned medium. After 5 days, EBs were transferred to 
gelatin-coated plates and subsequently cultured for another 14 days in knockout DMEM 
(Invitrogen) supplemented with 20% FBS, 1mML-glutamine, 1% non-essential amino acids, 
0.1mM b-mercaptoethanol, and penicillin/streptomycin. For qRT–PCR, iPS colonies were 
mechanically isolated and re-plated on Matrigelcoated plates in MEF-conditioned medium. 
After 2 days, medium was replaced with medium for each of the three germ layers. 
Endodermal differentiation: RPMI1640 medium supplemented with 2% FBS, 100 ng ml-1 
activin A (R&D Systems), L-glutamine and penicillin/streptomycin for 3 weeks. For 
mesodermal differentiation: knockout DMEM supplemented with 100 mM ascorbic acid 
(Sigma), 20% FBS, 1mM L-glutamine, 1% non-essential amino acids, 0.1mM b-
mercaptoethanol and penicillin/streptomycin for 3 weeks. For ectodermal differentiation: the 
cells were maintained in N2B27 medium for 7 days and the medium replaced with N2 
medium supplemented with 10 ng ml-1 bFGF2 (peprotech), 100 ng ml-1 Sonic Hedgehog (R&D 
Systems), 10 ng ml-1 PDFG (R&D Systems), L-glutamine and penicillin/streptomycin for 2 
weeks. The medium was changed every other day. Furthermore, we could generate human 
normal hepatocytes from ChiPS cells in vitro, according to method of previous report (Ref. S1). 
2.6 Bisulfite sequencing 
Genomic DNA (1 mg) was treated with a CpGenome DNA modification kit (Chemicon) 
according to the manufacturer’s recommendations. Treated DNA was purified with a QIA 
quick column (QIAGEN). The promoter regions of the human Oct3/4 and Nanog genes 
were amplified by PCR. The PCR products were subcloned into pCR2.1-TOPO. Ten clones 
of each sample were verified by sequencing with the M13 universal primer. Primer 
sequences used for PCR amplification were provided in a previous report (3). 
2.7 Karyotyping and DNA fingerprinting analysis 
Chromosomal G-band analyses and DNA fingerprinting analysis were performed in our 
laboratories. 
2.8 Teratoma formation 
Teratoma formation was performed as previously described (3). 
2.9 Primers for RT-PCR gene primer sequence 
Primers for RT-PCR gene primer sequence were performed as previously described (3). As 
for β-catenin, the primers for RT-PCR gene primer sequence was also performed as 
previously described (Ref. S1).  
2.10 The evaluation of cancerous risk for the humsn iPS cell lines 
The ChiPS cell lines as human iPS cell lines were inoculated intramuscularly into 
immunodeficient mice (Rag2-/- Il2rg-/-). Then, we compared microvessel density (MVD) 
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within teratomas in mice between both groups (p21 knockdown and control group). As for 
angiogenesis in teratomas from ChiPS cell lines, microvessel density (MVD) per high-
powered field (h.p.f.) of teratomas was quantified by human-specific anti-CD31 
immunofluorescence. N = 3–6; All values were mean ± s.e.m. 
3. Results 
3.1 The generation of human induced pluripotent stem (iPS) cells  
In O hour time point, though the expression of Oct3/4 was found and the each 
expressions of Sox2, Klf4 and Nanog was slight, Oct3/4, Sox2, Klf4 and Nanog were 
reactivated during the administration of chemicals (Fig. 1). However, by stopping of the 
administration, the reactivations for the expressions of each pluripotency-associated genes 
were silenced. 
Around day 14 after the administration of chemicals, we observed human hES cell-like 
colonies (Fig. 2). The cells expressed hES cell-specific surface antigens, including SSEA-4, 
tumor-related antigen (TRA)-1-60, TRA-1-81 and Nanog protein (Fig. 3).  
Furthermore, reverse transcription polymerase chain reaction (RT-PCR) showed that the 
cells expressed many undifferentiated ES cell-marker genes such as Oct3/4, Sox2, Nanog, 
etc, at levels equivalent to the hES cell line H9 (Fig. S1). Moreover, by Western blotting, 
protein levels of Oct3/4, Sox2, Nanog, etc were similar between the cells and hES cells  
(Fig. S2).  
On the other hand, bisulfite genomic sequencing analyses evaluating the methylation status 
of cytosine guanine dinucleotides (CpG) in the promoter regions of pluripotent-associated 
genes, such as Oct3/4 and Nanog, revealed that they were highly unmethylated (Fig. 4). 
Thus, the cells were more similar to hES cells. We designated the human iPS cells as 
Chemicals-human induced pluripotent stem (ChiPS) cells.  
Furthermore, in order to test pluripotency in vivo, we transplanted the ChiPS cell lines as 
human iPS cell lines subcutaneously into the dorsal flanks of immunodeficient (SCID) mice. 
Nine weeks after injection, we observed tumor formation. Histological examination showed 
that the tumor contained neural tissues (ectoderm), striated muscle (mesoderm), and gut-
like epithelial tissues (endoderm) (Fig. 5), demonstrating that the cells were pluripotent. 
Moreover, we confirmed the expression of markers for all three germ layers by qRT-PCR 
analysis (Fig. 6).  
On the other hand, chromosomal G-band analyses showed that human iPS cells had a 
normal karyotype of 46 XY (Fig. 7). In addition, DNA fingerprinting analysis confirmed that 
human iPS cells were liver progenitor cells origin (Data not shown). Thus, human iPS cells 
clones were derived from liver progenitor cells and were not a result of cross-contamination. 
Therfore we could generate ChiPS cells as human iPS cells from human cells by only 
chemicals. 
3.2 The risk evaluation of malignant transformations for the human iPS cells lines  
By using MVD within SCID mice that ChiPS cell lines as human iPS cell lines were 
transplanted, we performed the risk evaluation of malignant transformations for the cell 
lines (Fig. 8). The ChiPS cell lines between the p21 knockdown group and the control group 
were inoculated intramuscularly into immunodeficient mice (Rag2-/- Il2rg-/-). Then, we 
compared microvessel density (MVD) within teratomas in mice between the both groups. 
As a result, the MVD was significantly reduced within teratomas derived from the latter 
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compared to the former (P<0.01). Though cancer risk of patients with down’s syndrome was 
less than healthy people and the MVD in the case of human iPS cells derived from patients 
with down’s syndrome was also less than the MVD in the case of human iPS cells derived 
from healthy people (4), the MVD in control group of the present study was equal to the 
case (4) of patients with down’s syndrome (Fig. 8 and Ref. 4). 
Therefore, our observation shows the increased risk for malignant transformations of ChiPS 
cells by the p21 knockdown (Fig.8), and the induction of p21 is necessary to avoid malignant 
transformations of ChiPS cells as human iPS cells. 
4. Discussion 
We could generate human iPS cells from human liver progenitor cells by only chemicals. 
The human iPS cells were similar to hES cells in morphology, proliferation, surface antigens, 
gene expression, and epigenetic status of pluripotent cell-specific genes. Furthermore, these 
cells could differentiate into cell types of the three germ layers in vitro and in teratomas. The 
reprogramming efficiency of generating ChiPS cells as human iPS cells ranged from 0.05%. 
Therefore, the efficiency was improved more than previous reports (3) (5) (6) (7). 
Moreover, though we previously found the induction of p21 was necessary to avoid 
malignant transformations of human iPS cells (8), the result was also true of the case of 
ChiPS cells in the present study. 
In conclusion, we could genetate ChiPS cells as human iPS cells from human cells by only 
two chemicals. Now, we try to generate human iPS cells from human normal somatic cells 
by chemicals used in this study. Perhaps, human iPS cells such as ChiPS cells would be 
useful as novel drug screening system in the near future (Fig. 9). 
5. Figures and legends 
 
Fig. 1. Pluripotency-associated genes during treatment of human liver progenitor cells.  
Total RNA was prepared after various periods of time (6, 12, 24, 48 and 96 hr) and analyzed 
by reverse transcription-polymerase chain reaction for embryonic and pluripotency-
associated genes (Oct3/4, Nanog, Klf4 and Sox2) and. Loading control, β –actin 
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Fig. 2. Typical image of hES cell-like colony (ChiPS cells as human iPS cells) 
 
  
 
  
Fig. 3. Typical immunocytochemistry for SSEA-4, TRA-1-60, TRA-1-81, and Nanog (human 
iPS cells clone). Nuclei were stained with Hoechst 33342 (blue). Bars = 100 mm 
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Fig. S1. RT-PCR analysis of ES cell-marker genes in human iPS cells 
 
 
Fig. S2. Western blot analysis of ES cell-marker genes in human iPS cells 
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Left; Oct3/4 (human ES), Right; Oct3/4 (human iPS) 
 
 
 
 
 
Left; Nanog (human ES), Right; Nanog (human iPS) 
 
Fig. 4. Methylation analysis of Oct3/4 and Nanog promoter regions in human iPS cells. 
Bisulfite gemomic sequencing of the promoter region of Oct3/4 and Nanog in iPS cells, 
human ES cells. The open circles indicate unmethylated CpG dinucleotides, while the closed 
circles indicate methylated CpG.s 
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Left (Muscle), Center (Neural tissue), Right (Gut-like epithelium) 
 
Fig. 5. Teratoma formation in human iPS cells 
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Fig. 6. In vitro differentiation of human iPS cells into all three germ layers. Quantitative PCR 
analyses of all three germ layer markers from differentiated human iPS cells after directed 
differentiation: mesoderm (HAND1, FOXF1), endoderm (AFP, GATA6, SOX17) and 
ectoderm (PAX6, SOX1, NCAM1). Data denote beta-actin-normalized fold changes relative 
to undifferentiated parental human iPS cells 
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Fig. 7. Chromosomal G-band analysis in typical human iPS cells 
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Fig. 8. The risk evaluation of malignant transformation for Chips cells as humsn iPS cell lines 
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Fig. 9. A novel drug screening system by using Chips cells as human iPS cells 
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